Home › Prostate Cancer › Washington
Prostate Cancer clinical trials in Washington
55 studies for Prostate Cancer are looking for participants at sites in Washington.
Cities in Washington
- Seattle45 studies
- Tacoma11 studies
- Spokane Valley9 studies
- Kirkland7 studies
- Spokane7 studies
- Kennewick5 studies
- Bellingham5 studies
- Renton5 studies
- Everett4 studies
- Walla Walla4 studies
- Longview4 studies
- Vancouver4 studies
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- and 19 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 13, 2026 · NCT04423211Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · Men · Updated Nov 12, 2026 · NCT04221542Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Kadlec Clinic Hematology and Oncology, Kennewick
- Valley Medical Center, Renton
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03866382The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- University of Washington Medical Center, Seattle
RecruitingPhase 2
Ages 18 and older · Men · Updated Nov 5, 2026 · NCT07745361Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- and 20 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06632977A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Swedish Medical Center, Seattle
RecruitingPhase 1
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT06095089Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT07200830A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · Men · Updated Nov 3, 2026 · NCT07082920Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · Men · Updated Nov 2, 2026 · NCT07466498A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- VA Puget Sound Health Care System ( Site 0054), Seattle
- Fred Hutchinson Cancer Center ( Site 0060), Seattle
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 30, 2026 · NCT06925737Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1
Ages 18 and older · Men · Updated Oct 27, 2026 · NCT05997615A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
RecruitingPhase 2
Ages 18 and older · Men · Updated Oct 26, 2026 · NCT05593497Precision-Based Genomics in Prostate Cancer
- University of Washington, Seattle
RecruitingObservational study
Ages 18 to 120 · Men · Updated Oct 26, 2026 · NCT04706663Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- and 2 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 23, 2026 · NCT05946213Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingObservational study
Ages 18 and older · Men · Updated Oct 22, 2026 · NCT04489719A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 105, Spokane
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT05914116A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Spokane Urology ( Site 0035), Spokane
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06136650A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Northwest Medical Specialties, PLLC, Tacoma
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 20, 2026 · NCT07213674Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · Men · Updated Oct 19, 2026 · NCT07698535AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Research Site, Tacoma
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 19, 2026 · NCT07611110Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Research Site, Spokane
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 15, 2026 · NCT07711002Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Swedish Medical Center, Seattle
- Northwest Medical Specialties, Tacoma
RecruitingPhase 3
Ages 18 to 100 · Men · Updated Oct 15, 2026 · NCT06855277This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Northwest Medical Specialties, PLLC, Bonney Lake
- Northwest Medical Specialties, PLLC, Federal Way
- Northwest Medical Specialties, PLLC, Gig Harbor
- and 2 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 14, 2026 · NCT07028853Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- FHCC Overlake, Bellevue
- Seattle Cancer Care Alliance at EvergreenHealth, Kirkland
- FHCC South Lake Union, Seattle
- and 2 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 8, 2026 · NCT03678025The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT06801236Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 2/3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06780670High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT05011383Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT04038502PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
- University of Washington Medical Center, Seattle
RecruitingObservational study
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT04995198The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
- University of Washington, Seattle
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 14, 2026 · NCT06111781Prostate Active Surveillance Study
- Veterans Affairs Puget Sound Health Care System, Seattle
- University of Washington, Seattle
RecruitingObservational study
Ages 21 and older · Men · Updated Sep 2, 2026 · NCT00756665A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 21, 2026 · NCT06844383A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
- Northwest Medical Specialties, PLLC - Tacoma, Tacoma
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 17, 2026 · NCT06842498Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 14, 2026 · NCT04812366Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Aug 11, 2026 · NCT06236139A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 10, 2026 · NCT06067841Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
All ages · Men · Updated Aug 6, 2026 · NCT06145633From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.